Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC3153 | TNBC | Basal A | Celecoxib | COX2 | COX | 1670 | uM | 10577.136 | 0.9318 | 0.8632 | 0.9962 | |
| HCC38 | TNBC | Basal B | Celecoxib | COX2 | COX | 0.00427 | uM | 10578.136 | 0.9543 | 0.9409 | 1.5577 | |
| HCC38 | TNBC | Basal B | Celecoxib | COX2 | COX | 0.0213 | uM | 10578.136 | 0.9513 | 0.9370 | 1.5577 | |
| HCC38 | TNBC | Basal B | Celecoxib | COX2 | COX | 0.107 | uM | 10578.136 | 0.9794 | 0.9734 | 1.5577 | |
| HCC38 | TNBC | Basal B | Celecoxib | COX2 | COX | 0.533 | uM | 10578.136 | 0.9710 | 0.9626 | 1.5577 | |
| HCC38 | TNBC | Basal B | Celecoxib | COX2 | COX | 2.67 | uM | 10578.136 | 1.0101 | 1.0130 | 1.5577 | |
| HCC38 | TNBC | Basal B | Celecoxib | COX2 | COX | 13.3 | uM | 10578.136 | 0.9849 | 0.9805 | 1.5577 | |
| HCC38 | TNBC | Basal B | Celecoxib | COX2 | COX | 66.7 | uM | 10578.136 | 0.9977 | 0.9970 | 1.5577 | |
| HCC38 | TNBC | Basal B | Celecoxib | COX2 | COX | 333 | uM | 10578.136 | 0.9721 | 0.9640 | 1.5577 | |
| HCC38 | TNBC | Basal B | Celecoxib | COX2 | COX | 1670 | uM | 10578.136 | 1.0501 | 1.0638 | 1.5577 | |
| MDA-MB-134-VI | HR+ | Luminal | Celecoxib | COX2 | COX | 0.00427 | uM | 10519.136 | 0.9228 | 0.8639 | 1.1406 | |
| MDA-MB-134-VI | HR+ | Luminal | Celecoxib | COX2 | COX | 0.0213 | uM | 10519.136 | 0.9453 | 0.9038 | 1.1406 | |
| MDA-MB-134-VI | HR+ | Luminal | Celecoxib | COX2 | COX | 0.107 | uM | 10519.136 | 0.9589 | 0.9277 | 1.1406 | |
| MDA-MB-134-VI | HR+ | Luminal | Celecoxib | COX2 | COX | 0.533 | uM | 10519.136 | 0.9927 | 0.9872 | 1.1406 | |
| MDA-MB-134-VI | HR+ | Luminal | Celecoxib | COX2 | COX | 2.67 | uM | 10519.136 | 0.9695 | 0.9464 | 1.1406 | |
| MDA-MB-134-VI | HR+ | Luminal | Celecoxib | COX2 | COX | 13.3 | uM | 10519.136 | 0.9819 | 0.9682 | 1.1406 | |
| MDA-MB-134-VI | HR+ | Luminal | Celecoxib | COX2 | COX | 66.7 | uM | 10519.136 | 0.9770 | 0.9597 | 1.1406 | |
| MDA-MB-134-VI | HR+ | Luminal | Celecoxib | COX2 | COX | 333 | uM | 10519.136 | 1.0006 | 1.0010 | 1.1406 | |
| MDA-MB-134-VI | HR+ | Luminal | Celecoxib | COX2 | COX | 1670 | uM | 10519.136 | 0.9651 | 0.9386 | 1.1406 | |
| MDA-MB-175-VII | HR+ | Luminal | Celecoxib | COX2 | COX | 0.00427 | uM | 10642.136 | 0.9345 | 0.7553 | 0.5193 | |
| MDA-MB-175-VII | HR+ | Luminal | Celecoxib | COX2 | COX | 0.0213 | uM | 10642.136 | 0.9640 | 0.8638 | 0.5193 | |
| MDA-MB-175-VII | HR+ | Luminal | Celecoxib | COX2 | COX | 0.107 | uM | 10642.136 | 0.9453 | 0.7948 | 0.5193 | |
| MDA-MB-175-VII | HR+ | Luminal | Celecoxib | COX2 | COX | 0.533 | uM | 10642.136 | 0.9658 | 0.8703 | 0.5193 | |
| MDA-MB-175-VII | HR+ | Luminal | Celecoxib | COX2 | COX | 2.67 | uM | 10642.136 | 0.9467 | 0.7997 | 0.5193 | |
| MDA-MB-175-VII | HR+ | Luminal | Celecoxib | COX2 | COX | 13.3 | uM | 10642.136 | 0.9603 | 0.8499 | 0.5193 |